-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Frontier Bio was listed on the Shanghai Stock Exchange on October 28, 2020.
2019, Frontier Bio filed for an IPO in accordance with the fifth set of listing criteria in the company's listing rules.
the company's issue price of Rmb20.5 per share, with a net capital raising of Rmb1,717m, according to the company's results.
currently, Frontier Biology has a new drug on the market, two new drugs in the research phase of clinical trials.
, according to the prospectus, the company developed Aykonen, the world's first long-acting human immunodeficiency virus (HIV) fusion inhibitor.
Frontier Biology is a biopharmaceutical company founded in 2013 by Dr. Xie Dong, Dr. Wang Changjin and Dr. Lu Rongjian, dedicated to research, development, production and marketing of innovative drugs for major unseeded clinical needs.
according to the cutting-edge biological prospecto, the company uses a combination of independent research and development, authorized introduction and cooperative research and development to carry out new drug research and development.
this time on the Science and Technology Board, which means that cutting-edge organisms will enter a new stage of development.
, Frontier Biology has focused on new drug development in the field of long-acting peptides.
the company's own research and development of a new class of drugs, Aykonen (Abovetay) was approved for listing in China in May 2018.
Iconen is an HIV-1 fusion inhibitor that is suitable for use in combination with other antiretroviral drugs to treat hiv-1 infections that are still replicated by multiple other antiretroviral drugs.
According to the prospectus, Aykonin is not only the world's first long-acting HIV fusion inhibitor, but also the only approved anti-HIV long-acting injection drug approved in the Chinese market, given once a week, in combined with other anti-AIDS drug treatment can quickly and powerfully suppress the virus and improve immunity.
addition to Aykonen, Frontier Biology currently has two new drugs in clinical trials: one is the "Aykonen plus 3BNC117 combination therapy."
According to Frontier Biology Bulletin, 3BNC117 is a broad-spectrum, medium-sized antibody licensed by the company from Rockefeller University in the United States that not only inhibits HIV replication in the same way as other anti-AIDS drugs, but also mediates immune responses to HIV and infected cells.
, which uses Aykonin in a joint effort with 3BNC117, aims to maximize the suppression of different hiv viruses, including drug-resistant viruses, using different antiviral mechanisms in both molecules.
Frontier Biology intends to develop this combination therapy for the following four adaptations: (1) HIV multi-drug resistance therapy;
Frontier Biology began phase 2 clinical trials of combined therapy to maintain therapeutic adaptation in the United States at the end of 2018 and was approved for Phase 2 clinical trials in China in May 2019.
addition, in November 2019, the FDA granted fast-track eligibility for the combination therapy for the treatment of MDR (HIV multiple resistance).
drug in the study is AB001.
AB001 is a new type of permeable analgesic patch intended to treat muscle, bone and joint pain.
according to the prospectines, Frontier Life entered into an agreement with ABsize subsidiary Likida in 2014 to obtain exclusive development and commercial rights to the drug in Greater China, including Chinese mainland, Hong Kong and Taiwan.
According to the prospectuse, AB001 not only has a small molecular weight of the active ingredient of the drug, is easy to penetrate through the skin into the pain area, and plays an anti-inflammatory analgesic effect, but also greatly reduces the amount of drug exposure throughout the body, avoids gastrointestinal absorption and liver "first over effect", improves safety and reduces side effects.
, AB001 has completed Phase 2 clinical trials to treat back pain in the United States.
in China, AB001 has completed a bridding Phase 1 clinical trial and reached the preset endpoint target.
completed clinical trial data show that AB001 is more effective at relieving pain in patients with low back pain than placebos, while effectively reducing exposure to drugs throughout the body, avoiding common side effects of oral analgesics, and improving safety.
Frontier Biology Program applied to the Drug Review Center (CDE) of the State Drug Administration of China for exemption from Phase 2 clinical trials in China and to conduct critical Phase 3 clinical trials in China directly, based on the results of AB001 clinical trials in China and the United States.
Frontier Bio-Product Pipeline and Research and Development Progress (Screenshot Source: Frontier Bio Prospecto) Frontier Bio prospecto shows that the company's net capital raising of 1.717 billion yuan, will be mainly used to invest in the following projects: 1) 10 million HIV fusion inhibitor project for injection; 2) clinical research and development project for "Aykonin plus 3BNC117" combined therapy; 3) clinical research and development project for new permeable analgesic patch AB001; 4) marketing network construction project; 5) supplementary working capital.